SCHEMBL5675377

SCHEMBL5675377

CC1(C)OB(c2cccc(NC(=O)Nc3ccccc3)c2)OC1(C)C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 3/20 0.58
KDR P35968 3/20 0.58
KMT2A Q03164 5/20 0.51
MEN1 O00255 4/20 0.51
CA1 P00915 2/20 0.49
CA2 P00918 2/20 0.49
CA9 Q16790 2/20 0.49
MAPT P10636 5/20 0.49
RAB9A P51151 4/20 0.49
NPC1 O15118 3/20 0.49
TP53 P04637 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
HTT P42858 2/20 0.49
POLB P06746 1/20 0.49
MAPK1 P28482 1/20 0.49
HSD17B10 Q99714 1/20 0.49
LMNA P02545 1/20 0.49
EPHX1 P07099 1/20 0.49
TSHR P16473 1/20 0.49
EPHX2 P34913 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15932600 0.91 RAB9A (0.55) PDGFRBKDRKMT2AMEN1CA1
SCHEMBL423849 0.89 PDGFRB (0.54) PDGFRBKDRKMT2AMEN1MAPT
SCHEMBL556699 0.89 PDGFRB (0.46) PDGFRBKDRKMT2AMEN1CA1
SCHEMBL7139795 0.88 CA1 (0.48) PDGFRBKDRKMT2AMEN1CA1
SCHEMBL15932598 0.87 RAB9A (0.55) PDGFRBKDRKMT2AMEN1CA1
SCHEMBL423204 0.87 PDGFRB (0.61) PDGFRBKDRKMT2AMEN1CA1
SCHEMBL12350704 0.86 KCNK3 (0.58) KMT2AMEN1CA1CA2CA9
SCHEMBL12491436 0.86 MTOR (0.57) PDGFRBKDRKMT2AMEN1CA1
SCHEMBL15917735 0.86 CA2 (0.54) PDGFRBKDRKMT2AMEN1CA1
SCHEMBL561229 0.85 ALDH1A1 (0.50) PDGFRBKDRCA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060194823-A1 Sulfonamido-macrocycles as Tie2 inhibitors and the salts thereof, a pharmaceutical composition comprising these compounds, the method of preparing and the use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194823-A1 Sulfonamido-macrocycles as Tie2 inhibitors and the salts thereof, a pharmaceutical composition comprising these compounds, the method of preparing and the use thereof TEK, TIE1, KDR PDGFRB 15/4885KDR 3/4885KMT2A 335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.